You are here

Cancer Clinical Trials

The Koontz Center for Advanced Breast Cancer is the region’s first and only program dedicated to the treatment of metastatic breast cancer.

Learn how clinical trials can make all the difference in your treatment.


I Want to Know My Options

Please contact me about

The Koontz Center is currently enrolling patients in the following trials specifically targeting advanced breast cancer.

  • A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer. Learn more at
  • A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Learn more at
  • A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer. Learn more at
  • Phase II Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gencitabine and Carboplatin Chemotherapy. Learn more at
  • Phase III, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with Her2+ Metastatic Breast Cancer Who Have Received Prior Anti-Her2 Therapies and Require Systemic Treatment. Learn more at
  • A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Fulvestrant in Subjects with ER+ Breast Cancer. Learn more at
  • Development and Implementation of The Breast Cancer Collaborative Registry (BCCR). Learn more at
  • A Phase II, multi-centre Study of BGB324 in combination with Pembrolizumab in Patients with Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative or Triple Negative Inflammatory Breast Cancer. Learn more at
  • Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor (TRINITI-1). Learn more at

Learn More